Saxenda ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
193Prader-Willi syndrome3

193. Prader-Willi syndrome


Clinical trials : 111 Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-004415-37-NL
(EUCTR)
07/03/201617/08/2015Effect of liraglutide for weight management in children with Prader-Willi SyndromeEffect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period Obesity(Prader-Willi syndrome)
MedDRA version: 18.1;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE
Novo Nordisk A/SNULLNot RecruitingFemale: yes
Male: yes
60Phase 3France;United States;European Union;Canada;Turkey;Australia;Netherlands;Italy;New Zealand
2EUCTR2014-004415-37-IT
(EUCTR)
10/11/201529/07/2015Effect of liraglutide for weight management in children with Prader-Willi SyndromeEffect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period Obesity(Prader-Willi syndrome)
MedDRA version: 18.0;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE
Novo Nordisk A/SNULLNot RecruitingFemale: yes
Male: yes
60Phase 3France;United States;European Union;Canada;Turkey;Australia;Netherlands;New Zealand;Italy
3EUCTR2014-004415-37-FR
(EUCTR)
04/08/2015Effect of liraglutide for weight management in children with Prader-Willi SyndromeEffect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period Obesity(Prader-Willi syndrome)
MedDRA version: 18.0;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE
Novo Nordisk A/SNULLNot RecruitingFemale: yes
Male: yes
60Phase 3United States;France;European Union;Canada;Turkey;Australia;Netherlands;Italy;New Zealand